Drug intelligence / Profile preview

Universal Cancer Vaccine

Development stage: Preclinical
Lead developer: Renhaim
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics

Overview

Universal Cancer Vaccine is an mRNA-based therapeutic vaccine being developed by Renhaim. It is designed to encode shared tumor neoantigens—mutations that are common across different patients and cancer types—to elicit a broad anti-tumor immune response. By utilizing an "off-the-shelf" approach, this vaccine aims to provide a more accessible alternative to personalized neoantigen vaccines, which require individual patient sequencing and custom manufacturing. The vaccine is currently in the preclinical research stage for the treatment of various cancers.

Other names: Universal mRNA Cancer VaccineRenhaim Universal Cancer VaccineShared Neoantigen Cancer Vaccine

Targets

Shared tumor neoantigen

Beyond the preview

Go deeper on Universal Cancer Vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Universal Cancer Vaccine.

Explore the full profile